Effects of levosimendan combined with antiplatelet on myocardial injury and serum Periostin and sST2 levels in patients with heart failure after intervention of acute myocardial infarction
Objective To observe the effect of Levosimendan combined with dual antiplatelet on myocardial injury and serum levels of Periodin and sST2 in patients with heart failure after AMI intervention.Methods Totally 108 AMI patients with heart failure after interventional therapy in our hospital from January 2020 to September 2022 were selected as subjects.They were randomly divided into double antibody group(n=53)and Levosimendan group(n=55)by envelope method.Both groups were given routine treatment,the dual anti group was given dual antiplatelet treatment,and the Levosimendan group was given Levosimendan combined dual antiplatelet treatment.Compare the differences in myocardial injury indicators,NT proBNP,Pe-riodin,sST2,VS-2,and cardiac function between the two groups,and calculate the efficacy and incidence of cardiovascular adverse events between the two groups.Results After treatment,Troponin Ⅰ(cTnI),NT proBNP,Creatine kinase Isozyme(CK-MB),Periodin,sST2,Myoglobin(Myo)in the Levosimendan group and the double antibody group were all lower than those before treatment,and lower in the Levosimendan group(P＜0.05).VS-2 increased after treatment in the Levosimen-dan group and the double antibody group,and was higher in the Levosimendan group(P＜0.05).After treatment,the left ventricular end diastolic volume(LVEDV)and left ventricular end systolic volume(LVESV)in the Levosimendan group and the double antibody group were lower than those before treatment,and lower in the Levosimendan group(P＜0.05).The left ventricular Ejection fraction(LVEF)in the Levosimendan group and the double antibody group after treatment was higher than that before treatment,and that in the Levosimendan group was higher(P＜0.05).The total effective rate in the Levosi-mendan group was 90.91％higher than that in the double antibody group 75.47％(P＜0.05).Conclusion Levosimendan combined with dual antiplatelet therapy can alleviate myocardial injury,improve cardiac function,and regulate serum levels of Periodin and sST2 in patients with heart failure after AMI intervention.
LevosimendanDual antiplatelet therapyAcute myocardial infarctionHeart failureMyocardial injuryCardiac function
NETL
NSTL
万方数据
